Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Ligand Pharmaceuticals Incorporated
LGND
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.3B
$315.97
▲ +1.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$112.41 - $320.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 174.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Captisol proprietary technology platform enabling superior drug formulations and bioavailability
- Diversified portfolio across multiple therapeutic areas reducing revenue concentration risk
- Strategic licensing partnerships generating recurring royalty revenue streams
- Established commercial infrastructure and regulatory expertise for rapid market access
- Acquisition-focused strategy providing access to innovative technologies and approved products
Bear Case
2 risks
- Average volatility.
- Growth premium of 1.6x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Stable outlook
Strong revenue growth (60% YoY)
Value
Growth premium of 1.6x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+56.3% over 3m
Quality
Excellent
High-growth business (51% revenue growth, 99% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying LGND right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 14, 2026
Reported EPS of $1.63 vs $1.84 consensus (-11.4% surprise). Revenue of $51.7M vs $59.1M expected (-12.5%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-11.4%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+52%
+46%
+15%
+123%
+39%
+14%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$41.5M
$51.8M
$42.8M
$45.3M
$47.6M
$115.5M
$59.7M
$51.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-25.8%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$253.50
▼ -19.8% vs $315.97
Latest: RBC Capital · May 8, 2026
3 analysts covering